 Oncolytic virus therapy |
| OF THE INVENTION As used herein the term "human cells" means cells isolated from a human, or ... |
|
| Covalently cross-linked oligonucleotides |
| OF THE INVENTION In accordance with the objects of this invention novel, covalently cross-linked ... |
|
| Methods of inducing cancer cell death and tumor regression |
| The present invention provides methods of treating cancer in a patient (e.g., a mammal such as a ... |
|
| Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| OF THE INVENTION The present invention concerns injectable, biocompatible and biodegradable ... |
|
| Modification of polymer surfaces and molecular immobilization by photoreaction |
| OF THE INVENTION To obviate disadvantages associated with the modification methods presently ... |
|
| Wound and skin care compositions |
| What is claimed: 1. A composition comprising a dermatologically acceptable carrier and an effective ... |
|
| Water treatment apparatus |
| The embodiments of the invention in which an exclusive property or privilege is claimed are defined ... |
|
| Membrane cell |
| What we claim is: 1. A monopolar filter press electrolytic cell suitable for use in the ... |
|
| Encapsulating biological active substances into erythrocytes |
| We claim: 1. A process for the encapsulation in human or animal erythrocytes of at least one ... |
|
| Flow chamber and electro-manipulator incorporating same |
| Accordingly, an object of the present invention is to provide a flow chamber and an electro-... |
|
|
L-DOPA ethyl ester to treat Parkinson's disease
| Details |
Inventors: Milman, Isaac; Veinberg, Alexander; Atlas, Daphne; Melamed, Eldad;
Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem (Jerusalem, IL); Teva Pharmaceutical Industries Ltd. (Jerusalem, IL)
Primary Examiner: Criares; Theodore J.
Assistant Examiner:
Attorney, Agent or Firm: White; John P.
Patients suffering from Parkinson's disease are treated by administering a composition which contains an active ingredient and a pharmaceutically acceptable carrier. The active ingredient comprises L-DOPA ethyl ester in an amount which is at least 97% by weight of the active ingredient and L-DOPA in an amount which is less than 1% by weight of the active ingredient. |
|
DETAILED DESCRIPTION OF THE INVENTION This invention provides a composition which comprises a pharmaceutically acceptable carrier and an active ingredient, such active ingredient comprising L-DOPA ethyl ester in an amount which is at least 97% by weight of such active ingredient and L-DOPA in an amount which is less than 1% by weight of such active ingredient.
The composition is further characterized by the fact that the L-DOPA ethyl ester content remains at least 97% by weight of the active ingredient after incubation for 6 months at 40.
degree.
C.
L-DOPA ethyl ester may be present in the composition as a free base.
This invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the active ingredient mentioned above with a therapeutically effective concentration of L-DOPA ethyl ester.
For the purposes of this invention "pharmaceutically acceptable carrier" means any of the standard pharmaceutical carriers.
Examples of suitable carriers are well known in the art and may include, but are not limited to, any of the standard pharmaceutical carriers.
In one embodiment of the invention the pharmaceutically acceptable carrier is an aqueous solution.
In another embodiment of the invention the aqueous solution is an acid buffered solution, such acid buffered solution may comprise hydrochloric, sulfuric, tartaric, phosphoric, ascorbic, citric, fumaric, maleic, or acetic acid.
In one embodiment of the invention the therapeutically effective concentration of L-DOPA ethyl ester is between about 10 and about 1,000 milligram equivalents of L-DOPA per milliliter.
In another embodiment of the invention the therapeutically effective concentration of L-DOPA ethyl ester is between about 50 and about 250 milligram equivalents of L-DOPA per milliliter.
The pharmaceutical composition preferably has a pH between about 1.
5 and about 5.
5.
This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of L-DOPA ethyl ester, an acidic solution as the pharmaceutically acceptable carrier, and an inhibitory amount of a decarboxylase inhibitor, such as carbidopa or benserazide, or of a MAO B inhibitor, such as deprenyl
|
|
Gene Therapy 
